PTC Therapeutics | PTCT - Sales Revenues

PTC Therapeutics reported $210.12M in Sales Revenues for its fiscal quarter ending in March of 2024.

Sales Change Date
Acadia Pharmaceuticals USD 231.04M 19.34M Dec/2023
Alnylam Pharmaceuticals USD 439.72M 310.81M Dec/2023
Amgen USD 8.2B 1.29B Dec/2023
Biogen USD 2.29B 96.3M Mar/2024
BioMarin Pharmaceutical USD 649M 2.79M Mar/2024
Cytokinetics USD 1.67M 1.29M Dec/2023
Daiichi Sankyo JPY 409.62B 37.3B Mar/2024
Gilead Sciences USD 7.12B 64M Dec/2023
Incyte USD 1.01B 94.32M Dec/2023
Ionis Pharmaceuticals USD 325M 180.79M Dec/2023
Ironwood Pharmaceuticals USD 117.55M 3.81M Dec/2023
Novartis USD 11.83B 54M Mar/2024
Pfizer USD 14.25B 1.02B Dec/2023
PTC Therapeutics USD 210.12M 96.94M Mar/2024
Roche Holding CHF 28.94B 842M Dec/2023
Sarepta Therapeutics USD 396.78M 64.96M Dec/2023
TG Therapeutics USD 43.97M 121.84M Dec/2023
Ultragenyx Pharmaceutical USD 127.39M 29.34M Dec/2023
Vertex Pharmaceuticals USD 2.52B 34.2M Dec/2023
Xencor USD 44.69M 14.48M Dec/2023